Lumbrokinase Reduced the Fibrinogen Concentration in Ischemic Cerebrovascular Disease Patients: A Systematic Review and Meta-Analysis
Abstract
Lumbrokinase has been used to treat stroke and cardiovascular disease. Fibrinogen elevation is a known risk factor and a powerful predictor of ischemic cerebrovascular disease. The objective of this study was to conduct a systematic review and meta-analysis of the effects of lumbrokinase treatment on fibrinogen concentration and blood and plasma viscosities. The search strategy included articles indexed by PubMed and other resources (Google Search), using medical subject headings (MeSH) and text words. A total of 185 articles were identified; however, only two articles were included in the final analysis, including 727 patients. The results demonstrated a significant reduction in the fibrinogen concentration (–0.67, 95% confidence interval [95% CI] [–1.22, –0.12]; p=0.02) and a significant reduction in plasma viscosity (–0.77, 95% CI [–1.06, –0.48]; p=0.00001) for the lumbrokinase-treatment group compared with the control group. However, no significant difference in blood viscosity was observed between the two groups (–0.61, 95% CI [–1.33, 0.11]; p=0.10). Lumbrokinase may be effective as an adjuvant drug alongside the standard treatment for ischemic cerebrovascular disease. However, these results should be interpreted with caution due to high heterogeneity, and further randomized controlled trials are necessary.
Keywords: Fibrinogen, ischemic cerebrovascular disease, lumbrokinase
Lumbrokinase Menurunkan Konsentrasi Fibrinogen pada Pasien Penyakit Iskemik Serebrovaskular: Kajian Sistematik dan Meta-Analisis
Abstrak
Lumbrokinase telah digunakan untuk penatalaksanaan strok dan penyakit kardiovaskular. Peningkatan konsentrasi fibrinogen telah diketahui sebagai faktor risiko dan prediktor yang sangat kuat untuk penyakit iskemik serebrovaskular. Tujuan review sistematik dan meta-analisis ini adalah untuk menganalisis efek lumbrokinase terhadap konsentrasi fibrinogen, viskositas darah dan viskositas plasma. Strategi pencarian artikel meliputi pencarian artikel pada database PubMed dan sumber lainnya (Worldwide Website/Google Search) dengan menggunakan medical subject heading (MeSH) dan textword. Sebanyak 185 artikel teridentifikasi, tetapi hanya 2 artikel (melibatkan 727 pasien) yang memenuhi kriteria inklusi. Hasil analisis menunjukkan bahwa lumbrokinase dapat menurunkan konsentrasi fibrinogen dibandingkan terhadap kelompok kontrol (–0,67, 95% CI [–1,22, –0,12] ; p=0,02). Selain itu, lumbrokinase juga dapat menurunkan viskositas plasma secara signifikan bila dibandingkan dengan kelompok kontrol (–0,77, 95% confidence interval [95% CI] [–1,06, –0,48]; p=0,00001). Efek lumbrokinase terhadap viskositas darah, meskipun terjadi penurunan terhadap viskositas darah, tidak menunjukkan signifikansi bila dibandingkan kelompok kontrol (–0,61, 95% CI [–1,33, 0,11]; p=0,10). Lumbrokinase mungkin efektif untuk penyakit iskemik serebrovaskular, namun hasil ini harus diinterpretasikan dengan hati-hati disebabkan heterogenitas yang tinggi, selain itu diperlukan lebih banyak penelitian dengan desain randomized controlled trial.
Kata kunci: Fibrinogen, lumbrokinase, penyakit iskemik serebrovaskular
Keywords
Full Text:
PDFReferences
Kollman JM, Pandi L, Sawaya MR, Riley M, Doolittle RF. Crystal structure of human fibrinogen. Biochemistry. 2009;48(18):3877–86. doi: 10.1021/bi802205g
Weisel JW, Litvinov RI. Fibrin formation, structure and properties. Subcell Biochem. 2017;82:405–56. doi: 10.1007/978-3-319-49674-0_13
Mosesson MW. Structure and functions of fibrinogen and fibrin. In: Tanaka K, Davie EW, Ikeda Y, Iwanaga S, Saito H, Sueishi K. Recent advances in thrombosis and hemostasis. Tokyo: Springer; 2008.
Luyendyk JP, Schoenecker JG, Flick MJ. The multifaceted role of fibrinogen in tissue injury and inflammation. Blood. 2019;133(6):511–20. doi: 10.1182/blood-2018-07-818211
Rothwell PM, Howard SC, Power DA, Gutnikov SA, Algra A, van Gijn J, et al. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke. 2004;35(10):2300–5. doi: 10.1161/01.STR.0000141701.36371.d1.
Pikija S, Trkulja V, Mutzenbach JS, McCoy MR, Ganger P, Sellner J. Fibrinogen consumption is related to intracranial clot burden in acute ischemic stroke: A retrospective hyperdense artery study. J Transl Med. 2016;14:250. doi: 10.1186s12967-016-1006-6
Beg M, Nizami A, Singhal KC, Mohammed J, Gupta A, Azfar SF. Role of serum fibrinogen in patients of ischemic cerebrovascular disease. Nepal Med Coll J. 2007;9(2):88–92.
Lee SJ, Hong JM, Lee SE, Kang DR, Ovbiagele B, Demchuk AM, et al. Association of fibrinogen level with early neurological deterioration among acute ischemic stroke patients with diabetes. BMC Neurol. 2017;17:101. doi: 10.1186/s12883-017-0865-7
Turaj W, Słowik A, Dziedzic T, Pułyk R, Adamski M, Strojny J, et al. Increased plasma fibrinogen predicts one-year mortality in patients with acute ischemic stroke. J Neurol Sci. 2006;246(1–2):13–9. doi: 10.1016/j.jns.2006.01.020
Wang KY, Tull L, Cooper E, Wang N, Liu D. Recombinant protein production of earthworm lumbrokinase for potential antithrombotic application. Evid Based Complement Alternat Med. 2013;2013:783971. doi: 10.1155/2013/783971
Ji H, Wang L, Bi H, Sun L, Cai B, Wang Y, et al. Mechanisms of lumbrokinase in protection of cerebral ischemia. Eur J Pharmacol. 2008;590(1–3):281–9. doi: 10.1016/j.ejphar.2008.05.037
Li GQ, Wang KY, Li D, Wang N, Liu D. Cloning, expression and characterization of a gene from earthworm Eisenia fetida encoding a blood-clot dissolving protein. PLoS One. 2012;7(12):e53110. doi: 10.1371/journal.pone.0053110
Cooper R, Kuh D, Hardy R; Mortality Review Group; FALCon and HALCyon Study Teams. Objectively measured physical capability levels and mortality: Systematic review and meta-analysis. BMJ. 2010;341:c4467. doi: 10.1136/bmj.c4467
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi: 10.1371/journal.p med.1000097
Cao YJ, Zhang X, Wang WH, Zhai WQ, Qian JF, Wang JS, et al. Oral fibrinogen-depleting agent lumbrokinase for secondary ischemic stroke prevention: Results from a multicenter, randomized, parallel-group and controlled clinical trial. Chin Med J. 2013;126(21):4060–5. doi: 10.3760/cma.j.issn.0366.-6999.20131332
Pang SQ, Ding MC, Xie SP, Chai XQ, Deng LY, Fu HL, et al. A clinical study of therapeutic effectiveness intreating ischemic cerebrovascular disease with lumbrokinase. Chin J Neurol Psychiat. 1993;4(26):1–5.
Hao Z, Liu M, Counsell C, Wardlaw JM, Lin S, Zhao X. Fibrinogen depleting agents for acute ischaemic stroke. Cochrane Database Syst Rev. 2012;3:CD000091. doi: 10.1002/14651858.CD000091.pub2
Haritha B, Sangeetha B, Sreevani M. Fibrinogen levels in ischemic stroke. IOSR-JPBS. 2015;10(3):91–8. doi: 10.9790/3008-10329198
Abdelgawad DM, Elbassiouny AA, Youssef RA, Eldin NS, Elrakawy MH. Elevated plasma fibrinogen levels predict poor clinical outcome after acute ischemic stroke. Egypt J Neurol Psych Neurosurg 2014;51(1):61–7.
Mandal SK, Majumder M, Hossain MS, Sarker M. Serum ferritin and plasma fibrinogen level in acute ischemic stroke. Bangladesh J Med Biochem. 2017;10(1): 16–20. doi: 10.3329/bjmb.v10i1.36694
Cho HM, Kang DR, Kim HC, Oh SM, Kim BK, Suh Il. Association between fibrinogen and carotid atherosclerosis according to smoking status in a Korean male population. Yonsei Med J. 2015;56(4):921–7. doi: 10.3349/ymj.2015.56.4.921
DOI: https://doi.org/10.15416/ijcp.2020.9.1.43
Refbacks
- There are currently no refbacks.
Indonesian Journal of Clinical Pharmacy is indexed by
